Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.

Xu C, Yan Z, Zhou L, Wang Y.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1417-24. doi: 10.1007/s00432-013-1458-5. Epub 2013 Jun 7.

PMID:
23743582
2.

Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis.

Jia X, Liu J, Gao Y, Huang Y, Du Z.

Arch Med Res. 2014 Oct;45(7):580-8. doi: 10.1016/j.arcmed.2014.11.002. Epub 2014 Nov 13. Review.

PMID:
25446613
3.
4.

Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.

Jeon Y, Jang ES, Choi YS, Kim JW, Jeong SH.

Clin Mol Hepatol. 2016 Sep;22(3):359-365. Epub 2016 Sep 25.

5.

Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.

Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P.

J Gastroenterol Hepatol. 2010 Jan;25(1):129-37. doi: 10.1111/j.1440-1746.2009.05988.x. Epub 2009 Sep 27.

PMID:
19793164
6.

Serological tumor markers of hepatocellular carcinoma: a meta-analysis.

Hussein TD.

Int J Biol Markers. 2015 Feb 24;30(1):e32-42. doi: 10.5301/jbm.5000119.

PMID:
25450646
7.

GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.

Attallah AM, El-Far M, Omran MM, Abdelrazek MA, Attallah AA, Saeed AM, Farid K.

Tumour Biol. 2016 Sep;37(9):12571-12577. Epub 2016 Jul 5.

PMID:
27380057
8.

Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma.

Yu JP, Xu XG, Ma RJ, Qin SN, Wang CR, Wang XB, Li M, Li MS, Ma Q, Xu WW.

J Clin Lab Anal. 2015 Mar;29(2):85-93. doi: 10.1002/jcla.21733. Epub 2014 Mar 28.

PMID:
24687454
9.

Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis.

Yi X, Yu S, Bao Y.

Clin Chim Acta. 2013 Oct 21;425:212-20. doi: 10.1016/j.cca.2013.08.005. Epub 2013 Aug 13. Review.

PMID:
23954771
10.

Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.

Li B, Liu H, Shang HW, Li P, Li N, Ding HG.

Afr Health Sci. 2013 Sep;13(3):703-9. doi: 10.4314/ahs.v13i3.26.

11.

Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis.

Zhou Y, Yin X, Ying J, Zhang B.

BMC Cancer. 2012 Jan 16;12:17. doi: 10.1186/1471-2407-12-17. Review.

12.

Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.

Ozkan H, Erdal H, Koçak E, Tutkak H, Karaeren Z, Yakut M, Köklü S.

J Clin Lab Anal. 2011;25(5):350-3. doi: 10.1002/jcla.20484.

PMID:
21919070
13.

Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature.

Yang SL, Fang X, Huang ZZ, Liu XJ, Xiong ZF, Liu P, Yao HY, Li CH.

Dis Markers. 2014;2014:127831. doi: 10.1155/2014/127831. Epub 2014 Oct 14. Review.

14.

Diagnostic Value of the Combination of Golgi Protein 73 and Alpha-Fetoprotein in Hepatocellular Carcinoma: A Meta-Analysis.

Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S.

PLoS One. 2015 Oct 6;10(10):e0140067. doi: 10.1371/journal.pone.0140067. eCollection 2015.

15.

Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.

Sun B, Huang Z, Wang B, Yu Y, Lin S, Luo L, Wang Y, Huang Z.

Med Sci Monit. 2017 Feb 16;23:850-855.

16.

Sensitivity and specificity of Dickkopf-1 protein in serum for diagnosing hepatocellular carcinoma: a meta-analysis.

Zhang J, Zhao Y, Yang Q.

Int J Biol Markers. 2014 Dec 9;29(4):e403-10. doi: 10.5301/jbm.5000101.

PMID:
24980448
17.

Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.

Jia X, Gao Y, Zhai D, Liu J, Cai J, Wang Y, Jing L, Du Z.

Technol Cancer Res Treat. 2016 Dec;15(6):780-786. Epub 2015 Sep 14.

PMID:
26370140
19.

Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.

Wang Y, Yang H, Xu H, Lu X, Sang X, Zhong S, Huang J, Mao Y.

J Gastroenterol Hepatol. 2014 Mar;29(3):597-602. doi: 10.1111/jgh.12461.

PMID:
24236824
20.

Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma.

Zhao Y, Wang M, Cui C, Zhang L, Liao F, Li H, Wu X.

Cancer Biomark. 2015;15(5):677-83. doi: 10.3233/CBM-150508.

PMID:
26406957

Supplemental Content

Support Center